| Feature | Specification |
|---|---|
| Application | Protein-Protein Interaction |
| Sample Volume | 10 µL |
You might also need
Don't forget your microplates
Features:
AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a biotinylated CD80 binds to the Streptavidin-coated Alpha Donor beads, while His tagged CTLA-4 is captured by Anti-His AlphaLISA Acceptor beads. When CD80 binding to CTLA-4 happens, Donor beads and Acceptor beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
Human Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also known as CD152 (cluster of differentiation 152), is a cell membrane receptor and a member of immunoglobulin superfamily. CTLA-4 is expressed once a T cell becomes active and modulates T cell signals by blocking the CD80 (B7.1) and CD86 (B7.2) ligands from binding to CD28. CTLA-4, functioning as an immune checkpoint, downregulates T cell immune responses. Because of its profound inhibitory role blocking CTLA-4 and CD80 or CD86 binding has been considered as promising therapeutic target for human autoimmune disease and cancers.
| Application |
Protein-Protein Interaction
|
|---|---|
| Automation Compatible |
Yes
|
| Brand |
AlphaLISA
|
| Detection Modality |
Alpha
|
| Product Group |
Kit
|
| Sample Volume |
10 µL
|
| Shipping Conditions |
Shipped in Blue Ice
|
| Target |
CTLA4,CD80
|
| Target Class |
Binding Assay
|
| Target Species |
Human
|
| Technology |
Alpha
|
| Therapeutic Area |
Immuno-oncology
|
| Unit Size |
500 assay points
|
Are you looking for resources, click on the resource type to explore further.
A single White Paper for a review of immuno-oncology
Immuno-oncology, the field which stimulates a individual's own immunity in...
Advance your autoimmune disease research and benefit from Revvity broad offering of reagent technologies
Chimeric antigen receptor (CAR) T-cell therapy has transformed the field of immuno-oncology providing a novel approach to treating...
Are you looking for technical documents related to the product? We have categorized them in dedicated sections below. Explore now or request your COA/TDS, SDS, or IFU/manual.
Loading...
We are here to answer your questions.